{"filings":[{"id":2106840,"accession_number":"0001104659-26-092064","cik":1124524,"company_name":"Cryoport, Inc.","ticker":"CYRX","form_type":"8-K","filed_at":"2026-08-06T20:30:48+00:00","items":["2.02","9.01"],"status":"ready","headline":"Cryoport Q2 2026 revenue $49.0M (+8% YoY); achieves positive adjusted EBITDA","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Revenue $49.0M, up 8% YoY; Life Sciences Services +15%, BioStorage/BioServices +25%.","Adjusted EBITDA from continuing operations positive $0.4M vs -$0.9M in Q2 2025.","Net loss attributable to common stockholders $0.20 per share (vs $2.13 income in Q2 2025, which included divestiture gain).","Supporting 779 clinical trials and 22 commercial CGT as of June 30, 2026.","Cash and short-term investments $396.7M; anticipate 11 possible BLA/MAA applications in H2 2026."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.65,"calibrated_materiality_score":0.65,"market_cap_usd":706640433.803725,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":947561,"accession_number":"0001104659-26-071892","cik":1124524,"company_name":"Cryoport, Inc.","ticker":"CYRX","form_type":"8-K","filed_at":"2026-06-09T21:00:27+00:00","items":["5.07","9.01"],"status":"ready","headline":"Cryoport shareholders elect directors, approve equity plan amendment at 2026 annual meeting","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["All six director nominees elected with substantial majority (e.g., Linda Baddour got 38.9M votes for).","Ratification of Deloitte as auditor for FY2026 approved (47.0M for, 21k against).","Advisory vote on executive compensation approved (39.5M for, 2.4M against).","Amendment to 2018 Omnibus Equity Incentive Plan to increase authorized shares approved (30.1M for, 12.6M against).","Fourth amendment to plan effective June 5, 2026; plan expires 10 years after."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.5,"calibrated_materiality_score":0.15,"market_cap_usd":706640433.803725,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":91427,"accession_number":"0001104659-26-054942","cik":1124524,"company_name":"Cryoport, Inc.","ticker":"CYRX","form_type":"8-K","filed_at":"2026-05-04T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Cryoport Q1 revenue $47.8M (+16% YoY); raises FY2026 guidance to $192-196M","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Q1 revenue $47.8M (+16% YoY); commercial CGT revenue $9.1M (+26%).","Life Sciences Services revenue $26.9M (+18%); BioStorage/BioServices up 21%.","Supported 766 global clinical trials (91 Phase 3) and 21 commercial CGTs as of March 31.","FY2026 revenue guidance raised to $192M-$196M versus prior outlook.","Four BLA/MAA filings in Q1; Rocket Pharma FDA approval for KRESLADI gene therapy."],"consensus_eps_estimate":null,"consensus_eps_actual":-0.25,"consensus_revenue_estimate":null,"consensus_revenue_actual":47798000.0,"consensus_period":"2026-Q1","consensus_source":"xbrl_only","sentiment":"positive","materiality_score":0.8,"calibrated_materiality_score":0.8,"market_cap_usd":706640433.803725,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":101497,"accession_number":"0001104659-26-022940","cik":1124524,"company_name":"Cryoport, Inc.","ticker":"CYRX","form_type":"8-K","filed_at":"2026-03-03T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Cryoport FY2025 revenue $176.2M (+12% YoY) beats guidance; FY2026 outlook $190-194M","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["FY2025 revenue $176.2M, up 12% YoY; Q4 revenue $45.5M, up 10% YoY.","Loss from continuing operations $34.0M; adjusted EBITDA from cont. ops -$5.8M (vs -$17.8M).","Commercial cell & gene therapy revenue $33.4M (+29% YoY); supported 760 clinical trials.","Life Sciences Services revenue $96.5M (+18%); BioStorage/BioServices up 22% to $18.4M.","Cash & investments $411.2M; repurchased 1.34M shares at avg $7.45 for $10.0M."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.7,"calibrated_materiality_score":0.7,"market_cap_usd":706640433.803725,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":117849,"accession_number":"0001104659-25-106421","cik":1124524,"company_name":"Cryoport, Inc.","ticker":"CYRX","form_type":"8-K","filed_at":"2025-11-04T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Cryoport Q3 revenue rises 15% to $44.2M; raises FY2025 guidance to $170-174M","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Q3 continuing ops revenue $44.2M (+15% YoY); gross margin 48.2% vs 45.5%.","Commercial Cell & Gene Therapy revenue up 36% YoY to $8.3M; supported 19 commercial therapies.","GAAP net loss attributable to common stockholders $8.9M ($0.18 loss per share) in Q3.","Adjusted EBITDA from continuing ops improved to -$0.6M from -$2.7M; cash/investments $421.3M.","Full-year 2025 revenue guidance raised to $170M-$174M from continuing operations."],"consensus_eps_estimate":null,"consensus_eps_actual":1.68,"consensus_revenue_estimate":null,"consensus_revenue_actual":130727000.0,"consensus_period":"2025-Q3","consensus_source":"xbrl_only","sentiment":"positive","materiality_score":0.75,"calibrated_materiality_score":0.75,"market_cap_usd":706640433.803725,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":134296,"accession_number":"0001104659-25-074314","cik":1124524,"company_name":"Cryoport, Inc.","ticker":"CYRX","form_type":"8-K","filed_at":"2025-08-06T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Cryoport Q2 revenue up 14% to $45.5M; cell & gene therapy revenue +33%; reaffirms FY25 guidance","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Net income of $105.2M includes $117.4M gain from CRYOPDP divestiture; adjusted EBITDA improved to -$0.9M vs -$5.6M a year ago.","Life Sciences Services revenue grew 21% to $24.4M (54% of total); BioStorage/BioServices up 28%.","Commercial cell & gene therapy revenue rose 33% to $8.7M; supported 18 commercial therapies and 728 global trials.","Closed strategic partnership with DHL and divestiture of CRYOPDP on June 11, 2025; cash & investments $426M.","Reaffirmed FY2025 revenue guidance of $165M–$172M, representing 5%-10% YoY growth."],"consensus_eps_estimate":null,"consensus_eps_actual":1.78,"consensus_revenue_estimate":null,"consensus_revenue_actual":86494000.0,"consensus_period":"2025-Q2","consensus_source":"xbrl_only","sentiment":"positive","materiality_score":0.75,"calibrated_materiality_score":0.75,"market_cap_usd":706640433.803725,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":151096,"accession_number":"0001558370-25-008613","cik":1124524,"company_name":"Cryoport, Inc.","ticker":"CYRX","form_type":"8-K","filed_at":"2025-06-13T23:59:59+00:00","items":["2.01","7.01","9.01"],"status":"ready","headline":"Cryoport completes CRYOPDP divestiture to DHL for ~$200M in cash; launches strategic partnership","summary_kind":"llm","event_type":"m_and_a","confidence":"high","bullets":["Total cash consideration of ~$200M: $133M purchase price plus repayment of $77.2M in intercompany loans.","Strategic partnership with DHL Group to collaborate on life sciences supply chain, expanding APAC and EMEA reach.","Pro forma net loss from continuing ops improves: Q1 2025 loss $7.3M vs. $9.0M reported; FY2024 loss $104.5M vs. $114.8M.","Company says deal provides capital to focus on advancing Life Science Services platform and Regenerative Medicine market.","Divested entity represented $71.6M revenue in FY2024; proceeds bolster cash to $246.3M pro forma as of March 31, 2025."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.75,"calibrated_materiality_score":0.75,"market_cap_usd":706640433.803725,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":151095,"accession_number":"0001104659-25-058019","cik":1124524,"company_name":"Cryoport, Inc.","ticker":"CYRX","form_type":"8-K","filed_at":"2025-06-10T23:59:59+00:00","items":["5.07"],"status":"ready","headline":"Cryoport stockholders elect all director nominees and set say-on-pay frequency at 1 year","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["All six director nominees elected with votes ranging from 35.2M to 39.5M; broker non-votes 3.8M.","Ratification of Deloitte & Touche as independent auditor approved with 36.6M for, 14.5K against.","Advisory vote on named executive officer compensation approved with 31.3M for, 1.5M against.","Stockholders selected a 1-year frequency for future say-on-pay votes (31.8M votes for 1 year).","Company will hold an advisory say-on-pay vote every year until the next frequency vote."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.25,"calibrated_materiality_score":0.15,"market_cap_usd":706640433.803725,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":151094,"accession_number":"0001104659-25-045557","cik":1124524,"company_name":"Cryoport, Inc.","ticker":"CYRX","form_type":"8-K","filed_at":"2025-05-07T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Cryoport Q1 revenue $41M, up 10% YoY; cell & gene therapy revenue up 33%","summary_kind":"llm","event_type":"earnings","confidence":"medium","bullets":["Commercial Cell & Gene therapy revenue $7.2M, up 33% YoY; supported 19 commercial therapies.","Life Sciences Services revenue $22.9M (+17%); Products $18.2M (+2%); total continuing ops $41.0M.","Strategic DHL partnership; CRYOPDP divestiture expected Q2/Q3 2025, providing capital infusion.","Supported 711 global clinical trials (net +36 YoY); 79 Phase 3; six BLA/MAA filings in Q1.","Abeona's ZEVASKYN FDA-approved post-Q1; 17 more application filings anticipated in 2025."],"consensus_eps_estimate":null,"consensus_eps_actual":-0.28,"consensus_revenue_estimate":null,"consensus_revenue_actual":41040000.0,"consensus_period":"2025-Q1","consensus_source":"xbrl_only","sentiment":"positive","materiality_score":0.75,"calibrated_materiality_score":0.75,"market_cap_usd":706640433.803725,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":169986,"accession_number":"0001104659-25-029642","cik":1124524,"company_name":"Cryoport, Inc.","ticker":"CYRX","form_type":"8-K","filed_at":"2025-03-31T23:59:59+00:00","items":["1.01","7.01","9.01"],"status":"ready","headline":"Cryoport sells CRYOPDP to DHL for $195M enterprise value, forms strategic partnership","summary_kind":"llm","event_type":"m_and_a","confidence":"high","bullets":["Divests CRYOPDP to DHL for total enterprise value of $195M; ~$138M cash plus repayment of ~$67M intercompany loans.","Strategic partnership formed with DHL to enhance global life sciences supply chain offerings.","Transaction expected to close in Q2 or Q3 2025, subject to regulatory approvals.","CRYOPDP handles over 600K shipments/year across 15 countries; DHL's pharma logistics revenue >EUR5B in 2024."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.85,"calibrated_materiality_score":0.85,"market_cap_usd":706640433.803725,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":169985,"accession_number":"0001104659-25-020404","cik":1124524,"company_name":"Cryoport, Inc.","ticker":"CYRX","form_type":"8-K","filed_at":"2025-03-04T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Cryoport reports FY 2024 revenue $228.4M (-2% YoY); guides FY 2025 revenue $240-250M","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["FY 2024 revenue $228.4M (down 2% YoY); Q4 revenue $59.5M (up 4% YoY).","Net loss attributable to common shareholders FY 2024 $122.8M ($2.49/sh) vs $107.6M ($2.21/sh) in FY 2023.","Commercial Cell & Gene therapy revenue grew 20% YoY to $25.9M in FY 2024.","Adjusted EBITDA negative $15.1M in FY 2024 vs negative $8.3M in FY 2023.","FY 2025 revenue guidance $240M-$250M; gross margin improved to 45.8% in Q4 2024."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.65,"calibrated_materiality_score":0.65,"market_cap_usd":706640433.803725,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":187024,"accession_number":"0001104659-24-115344","cik":1124524,"company_name":"Cryoport, Inc.","ticker":"CYRX","form_type":"8-K","filed_at":"2024-11-07T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Cryoport Q3 revenue flat YoY at $56.7M; services up 9%, product down 14%","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Net loss attributable to common stockholders: $1.2M ($0.02/share) vs $15.3M loss ($0.31) YoY.","Life Sciences Services revenue up 9% to $39.3M; gross margin improved to 46%.","Life Sciences Products revenue down 14% to $17.4M; total gross margin 44.8%.","Full-year 2024 revenue guidance reaffirmed at $225-235M; management targets positive adjusted EBITDA in 2025.","Repurchased $175M principal of 2026 convertible notes for $154.5M; cash and short-term investments $272.7M."],"consensus_eps_estimate":null,"consensus_eps_actual":-2.07,"consensus_revenue_estimate":null,"consensus_revenue_actual":168853000.0,"consensus_period":"2024-Q3","consensus_source":"xbrl_only","sentiment":"neutral","materiality_score":0.6,"calibrated_materiality_score":0.6,"market_cap_usd":706640433.803725,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":203560,"accession_number":"0001104659-24-086344","cik":1124524,"company_name":"Cryoport, Inc.","ticker":"CYRX","form_type":"8-K","filed_at":"2024-08-06T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Cryoport Q2 net loss $78M including $63.8M goodwill impairment; FY24 guidance cut to $225-235M","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Revenue $57.6M (+1% YoY, +5.5% sequentially); Life Sciences Services up 8%, Products down 10%.","GAAP EPS loss $1.62 (diluted); Adjusted EBITDA negative $3.8M vs. negative $1.3M a year ago.","Recorded $63.8M impairment charge related to MVE Biological Solutions goodwill write-off.","FY 2024 revenue guidance revised to $225-235M from prior range; expects positive adjusted EBITDA in 2025.","Announced $200M stock/note repurchase program; repurchased $160M of 2026 convertible notes for $141.6M."],"consensus_eps_estimate":null,"consensus_eps_actual":-2.05,"consensus_revenue_estimate":null,"consensus_revenue_actual":112189000.0,"consensus_period":"2024-Q2","consensus_source":"xbrl_only","sentiment":"negative","materiality_score":0.8,"calibrated_materiality_score":0.8,"market_cap_usd":706640433.803725,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":203559,"accession_number":"0001104659-24-086305","cik":1124524,"company_name":"Cryoport, Inc.","ticker":"CYRX","form_type":"8-K","filed_at":"2024-08-06T23:59:59+00:00","items":["8.01","9.01"],"status":"ready","headline":"Cryoport authorizes $200M repurchase program; repurchases $160M convertible notes at 11.5% discount","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Board authorized up to $200M repurchase of common stock and/or convertible notes, effective Aug 1, 2024 through Dec 31, 2027.","Repurchasing $160M principal of 0.75% Convertible Senior Notes due 2026 at 11.5% discount ($141.6M cash).","Transactions expected to close Aug 9, 2024; $186.2M principal remains outstanding from initial $402.5M.","CEO cites strong cash position enabling debt reduction while maintaining liquidity for growth."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.75,"calibrated_materiality_score":0.75,"market_cap_usd":706640433.803725,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":220030,"accession_number":"0001104659-24-064333","cik":1124524,"company_name":"Cryoport, Inc.","ticker":"CYRX","form_type":"8-K","filed_at":"2024-05-22T23:59:59+00:00","items":["5.07","9.01"],"status":"ready","headline":"Cryoport shareholders elect directors and approve equity plan amendment at 2024 annual meeting","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["All eight director nominees elected; Richard Berman received 20.5M votes for and 24.0M withheld.","Ratification of Deloitte & Touche as auditor for 2024: 47.4M for, 16,304 against, 10,342 abstain.","Advisory vote on executive compensation approved: 43.4M for, 1.0M against, 53,134 abstain.","Amendment to 2018 Omnibus Equity Incentive Plan to increase authorized shares approved: 42.0M for, 2.4M against."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.5,"calibrated_materiality_score":0.15,"market_cap_usd":706640433.803725,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":220029,"accession_number":"0001104659-24-058082","cik":1124524,"company_name":"Cryoport, Inc.","ticker":"CYRX","form_type":"8-K","filed_at":"2024-05-07T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Cryoport Q1 revenue falls 13% to $54.6M; net loss widens to $18.9M, adjusted EBITDA negative $7.7M","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Life Sciences Products revenue dropped 34% YoY to $17.8M, driven by slowdown in MVE cryogenic systems demand.","Life Sciences Services revenue rose 3% to $36.8M; BioStorage/BioServices up 9%.","Net loss attributable to common stockholders was $20.9M ($0.43 per share) vs $7.6M ($0.16) a year ago.","Full-year 2024 revenue guidance reaffirmed at $242-252M; CEO cites cost-reduction initiatives including workforce cuts.","Cryoport now supports 15 commercial cell & gene therapies; 675 global clinical trials as of March 31, 2024."],"consensus_eps_estimate":null,"consensus_eps_actual":-0.43,"consensus_revenue_estimate":null,"consensus_revenue_actual":54592000.0,"consensus_period":"2024-Q1","consensus_source":"xbrl_only","sentiment":"negative","materiality_score":0.7,"calibrated_materiality_score":0.7,"market_cap_usd":706640433.803725,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":239764,"accession_number":"0001104659-24-033491","cik":1124524,"company_name":"Cryoport, Inc.","ticker":"CYRX","form_type":"8-K","filed_at":"2024-03-12T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Cryoport FY 2023 revenue $233.3M (-2% YoY); net loss $99.6M; guides FY 2024 $242-252M","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Q4 revenue $57.3M (-5% YoY); FY revenue $233.3M (-2% YoY). Services grew 8% but product fell 14%.","Net loss for FY $99.6M includes $49.6M goodwill impairment; adjusted EBITDA negative $8.3M vs positive $13.9M prior year.","Commercial Cell & Gene therapy revenue up 33% YoY; BioStorage/BioServices up 45%; record 675 clinical trials supported.","FY 2024 revenue guidance $242-252M; expects progressive growth.","Cash, equivalents & short-term investments $456.8M; $36M remaining under $100M repurchase program."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"negative","materiality_score":0.8,"calibrated_materiality_score":0.8,"market_cap_usd":706640433.803725,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":239763,"accession_number":"0001104659-24-024562","cik":1124524,"company_name":"Cryoport, Inc.","ticker":"CYRX","form_type":"8-K","filed_at":"2024-02-15T23:59:59+00:00","items":["5.02","8.01","9.01"],"status":"ready","headline":"Cryoport appoints Edward Zecchini as SVP CDTO; CEO, CFO, CSO contracts amended through 2027","summary_kind":"llm","event_type":"leadership","confidence":"high","bullets":["Edward Zecchini resigned from Board effective Feb 19, 2024, to become Senior VP & Chief Digital & Technology Officer.","CEO Jerrell Shelton's agreement extended to Feb 15, 2027; termination without cause triggers full equity vesting, no COBRA.","CFO Robert Stefanovich and CSO Mark Sawicki agreements extended to Feb 15, 2027; termination without cause yields one-year accelerated vesting, reduced COBRA.","For all three, company non-renewal of contract is deemed termination without cause, entitling them to severance benefits.","No disagreements were reported with Zecchini's transition or the employment agreement amendments."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.4,"calibrated_materiality_score":0.4,"market_cap_usd":706640433.803725,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":257280,"accession_number":"0001104659-23-118697","cik":1124524,"company_name":"Cryoport, Inc.","ticker":"CYRX","form_type":"8-K","filed_at":"2023-11-15T23:59:59+00:00","items":["5.03","9.01"],"status":"ready","headline":"Cryoport amends bylaws to comply with SEC universal proxy rules","summary_kind":"llm","event_type":"other","confidence":"high","bullets":["Bylaw amendments effective Nov 9, 2023, update director nomination procedures.","Stockholders must provide representations and evidence of compliance with Rule 14a-19.","White proxy card reserved for Board; other solicitations require different color.","Failure to comply with Rule 14a-19 renders nominee ineligible; votes disregarded."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.25,"calibrated_materiality_score":0.25,"market_cap_usd":706640433.803725,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":257279,"accession_number":"0001104659-23-115766","cik":1124524,"company_name":"Cryoport, Inc.","ticker":"CYRX","form_type":"8-K","filed_at":"2023-11-08T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Cryoport Q3 revenue down 7% YoY, net loss widens to $0.31/share; affirms FY guidance","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Q3 revenue $56.2M (-7% YoY); net loss $15.3M ($0.31 loss per share) vs $7.3M ($0.15 loss) in Q3 2022.","Adjusted EBITDA negative $3.1M (vs positive $4.7M a year ago); operating costs rose to $41.2M.","Commercial cell/gene therapy revenue up 54% to $6.6M; supports record 670 clinical trials (81 Phase 3).","Affirms FY2023 revenue guidance $233-243M; cash & investments $465.9M at quarter end.","Repurchased $31.3M of convertible notes for $25.1M, recording $5.7M gain on debt extinguishment."],"consensus_eps_estimate":null,"consensus_eps_actual":-0.89,"consensus_revenue_estimate":null,"consensus_revenue_actual":175995000.0,"consensus_period":"2023-Q3","consensus_source":"xbrl_only","sentiment":"negative","materiality_score":0.75,"calibrated_materiality_score":0.75,"market_cap_usd":706640433.803725,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":274607,"accession_number":"0001104659-23-089376","cik":1124524,"company_name":"Cryoport, Inc.","ticker":"CYRX","form_type":"8-K","filed_at":"2023-08-09T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Cryoport Q2 revenue $57M (-11% YoY), net loss $18.4M; FY guidance $233-243M","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Revenue $57.0M, down 11% YoY; net loss attributable to common $20.4M ($0.42/share) vs. $11.2M loss a year ago.","MVE China revenue fell 67% YoY ($5.8M decline); slower client ramps also hit Biopharma/Pharma segment.","Bioservices revenue rose 38% to $3.2M; commercial therapy revenue up 9.2% to $4.3M.","Adjusted EBITDA was -$1.5M, down $7.5M YoY from $6.0M; net loss widened to $18.4M from $9.2M.","FY2023 revenue guidance $233-243M; cash & short-term investments $504.7M at June 30."],"consensus_eps_estimate":null,"consensus_eps_actual":-0.58,"consensus_revenue_estimate":null,"consensus_revenue_actual":119838000.0,"consensus_period":"2023-Q2","consensus_source":"xbrl_only","sentiment":"negative","materiality_score":0.75,"calibrated_materiality_score":0.75,"market_cap_usd":706640433.803725,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":274606,"accession_number":"0001104659-23-080348","cik":1124524,"company_name":"Cryoport, Inc.","ticker":"CYRX","form_type":"8-K","filed_at":"2023-07-12T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Cryoport expects Q2 revenue down 11% YoY; slashes FY2023 guidance to $233M-$243M","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Preliminary Q2 revenue $56.5M-$57.5M, down ~11% YoY; weak capital equipment demand.","FY2023 revenue guidance revised to $233M-$243M due to slower client ramps and trial delays.","Q2 impact from weaker global demand for capital equipment and clinical trial start delays.","CEO expects challenging conditions to persist into Q3 and Q4 2023.","Long-term outlook remains robust as cell and gene therapy industry CAGR expected >22%."],"consensus_eps_estimate":null,"consensus_eps_actual":-0.58,"consensus_revenue_estimate":null,"consensus_revenue_actual":119838000.0,"consensus_period":"2023-Q2","consensus_source":"xbrl_only","sentiment":"negative","materiality_score":0.8,"calibrated_materiality_score":0.8,"market_cap_usd":706640433.803725,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":291916,"accession_number":"0001104659-23-061489","cik":1124524,"company_name":"Cryoport, Inc.","ticker":"CYRX","form_type":"8-K","filed_at":"2023-05-16T23:59:59+00:00","items":["5.07"],"status":"ready","headline":"Cryoport AGM: high withhold votes for three directors; say-on-pay and auditor ratified","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Ramkumar Mandalam received 20.8M withhold votes; Robert Hariri 17.9M; Richard Berman 15.9M.","All eight director nominees elected; broker non-votes of 2.8M on proposals.","Ratification of Deloitte & Touche passed with 47.4M votes for, 10.9K against.","Advisory vote on executive compensation approved: 43.0M for, 1.6M against.","Annual meeting held on May 12, 2023."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.5,"calibrated_materiality_score":0.15,"market_cap_usd":706640433.803725,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":291915,"accession_number":"0001104659-23-056041","cik":1124524,"company_name":"Cryoport, Inc.","ticker":"CYRX","form_type":"8-K","filed_at":"2023-05-04T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Record Q1 revenue of $62.8M, up 20% YoY; net loss narrows to $0.16/share","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Revenue $62.8M, +20% YoY (+23% constant currency); Biopharma/Pharma +19%, Animal Health +30%, Reproductive Medicine +13%.","Net loss attributable to common stockholders $7.6M ($0.16/share) vs $15.4M ($0.31) YoY; adjusted EBITDA $2.9M vs $2.0M.","Commercial cell and gene therapy revenue +28% YoY; supports 652 clinical trials (82 Phase 3) and 10 commercial therapies.","Cash and short-term investments $522.6M; FY 2023 revenue guidance reaffirmed at $270-290M.","New partnerships with Syneos Health (jan 2023), Inception Fertility (Mar 2023), and Boston IVF (Apr 2023)."],"consensus_eps_estimate":null,"consensus_eps_actual":-0.16,"consensus_revenue_estimate":null,"consensus_revenue_actual":62817000.0,"consensus_period":"2023-Q1","consensus_source":"xbrl_only","sentiment":"positive","materiality_score":0.6,"calibrated_materiality_score":0.6,"market_cap_usd":706640433.803725,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":312666,"accession_number":"0001104659-23-037784","cik":1124524,"company_name":"Cryoport, Inc.","ticker":"CYRX","form_type":"8-K","filed_at":"2023-03-28T23:59:59+00:00","items":["5.02","9.01"],"status":"ready","headline":"Cryoport extends CFO Robert Stefanovich's employment agreement to Nov 1, 2026","summary_kind":"llm","event_type":"leadership","confidence":"high","bullets":["CFO employment term extended to November 1, 2026 via First Amendment to Employment Agreement dated March 24, 2023.","All other terms of the original agreement, including base salary and incentive compensation provisions, remain unchanged.","The amendment replaces prior automatic renewal provisions with a fixed term; no change in role or duties."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.25,"calibrated_materiality_score":0.25,"market_cap_usd":706640433.803725,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":312665,"accession_number":"0001104659-23-032821","cik":1124524,"company_name":"Cryoport, Inc.","ticker":"CYRX","form_type":"8-K","filed_at":"2023-03-15T23:59:59+00:00","items":["4.01","9.01"],"status":"ready","headline":"Cryoport dismisses EY as auditor, appoints Deloitte for FY 2023","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Audit Committee approved dismissal of Ernst & Young and appointment of Deloitte & Touche, effective March 9, 2023.","EY's reports for FY 2022 and 2021 contained no adverse opinion or qualification.","No disagreements or reportable events with EY during the past two fiscal years or subsequent interim period.","Deloitte subject to completion of standard client acceptance procedures and engagement letter.","EY letter filed as Exhibit 16.1 agreeing with the company's disclosures."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.5,"calibrated_materiality_score":0.5,"market_cap_usd":706640433.803725,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":312664,"accession_number":"0001104659-23-024795","cik":1124524,"company_name":"Cryoport, Inc.","ticker":"CYRX","form_type":"8-K","filed_at":"2023-02-23T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Cryoport reports Q4 2022 revenue $60.4M, full-year record $237.3M; guides FY2023 revenue $270-290M","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Full-year 2022 revenue $237.3M, up 7% YoY; commercial therapy revenue up 27% to $16.3M.","Net loss attributable to common stockholders $45.3M ($0.93/share) vs $283.7M ($6.18/share) in 2021.","Adjusted EBITDA $13.7M for 2022, down from $21.2M in 2021; Q4 adjusted EBITDA $0.7M.","Cash and short-term investments $523.3M at year-end; repurchased 1.6M shares for $37.9M in 2022.","FY2023 revenue guidance $270-290M (18% growth at midpoint); supporting 654 clinical trials and 10 commercial therapies."],"consensus_eps_estimate":null,"consensus_eps_actual":-0.93,"consensus_revenue_estimate":null,"consensus_revenue_actual":237277000.0,"consensus_period":"2022-FY","consensus_source":"xbrl_only","sentiment":"neutral","materiality_score":0.7,"calibrated_materiality_score":0.7,"market_cap_usd":706640433.803725,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":331174,"accession_number":"0001104659-22-114437","cik":1124524,"company_name":"Cryoport, Inc.","ticker":"CYRX","form_type":"8-K","filed_at":"2022-11-03T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Cryoport Q3 revenue up 7% to $60.5M, cuts FY 2022 guidance to $232-$238M on macro headwinds","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Q3 revenue $60.5M (+7% YoY); net loss $7.3M ($0.15/share); adj. EBITDA $4.7M vs $6.0M YoY.","Full-year 2022 revenue guidance cut to $232-$238M, citing FX, COVID China, supply chain, Ukraine war headwinds.","Supported 643 global clinical trials (+61 YoY); entered apheresis partnership with Takeda's BioLife.","Cash $530M; repurchased 1.34M shares for $33.3M at avg $24.84; $100M program authorized through 2025.","Gross margin 43.7% (+222 bps YoY); operating costs rose 22% to $34.2M."],"consensus_eps_estimate":null,"consensus_eps_actual":-0.69,"consensus_revenue_estimate":null,"consensus_revenue_actual":176919000.0,"consensus_period":"2022-Q3","consensus_source":"xbrl_only","sentiment":"negative","materiality_score":0.75,"calibrated_materiality_score":0.75,"market_cap_usd":706640433.803725,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":348745,"accession_number":"0001104659-22-086174","cik":1124524,"company_name":"Cryoport, Inc.","ticker":"CYRX","form_type":"8-K","filed_at":"2022-08-04T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Cryoport Q2 revenue up 14% to $64.2M; net loss widens to $0.23/sh; guidance reaffirmed","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Revenue $64.2M (+14% YoY, +18% constant currency); Biopharma/Pharma $51.7M (+14%).","Net loss to common $11.2M ($0.23/sh) vs $7.4M ($0.16) in Q2 2021; GAAP net loss $9.2M.","Adjusted EBITDA $6.0M, flat YoY; gross margin 45.0%, steady YoY and up 224bps sequentially.","FY2022 revenue guidance reaffirmed at $260M-$265M; $33.3M share repurchase completed at avg $24.84.","Record 626 clinical trials supported; opened new Global Supply Chain Centers; closed three acquisitions in Europe."],"consensus_eps_estimate":null,"consensus_eps_actual":-0.54,"consensus_revenue_estimate":null,"consensus_revenue_actual":116455000.0,"consensus_period":"2022-Q2","consensus_source":"xbrl_only","sentiment":"neutral","materiality_score":0.75,"calibrated_materiality_score":0.75,"market_cap_usd":706640433.803725,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":365510,"accession_number":"0001104659-22-056481","cik":1124524,"company_name":"Cryoport, Inc.","ticker":"CYRX","form_type":"8-K","filed_at":"2022-05-05T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Cryoport reports Q1 revenue of $52.3M, net loss $15.4M; FY2022 revenue guidance $260-265M","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Revenue $52.3M, down 2% YoY; net loss to common holders $15.4M ($0.31 loss per share) vs loss of $5.7M ($0.13) in Q1 2021.","Adjusted EBITDA $1.8M vs $7.2M in prior year; gross margin 42.7% vs 46.1%, impacted by $9.4M fire loss at New Prague plant.","Biopharma/Pharma revenue $43.0M (+1%); Animal Health $6.8M (-24%); Reproductive Medicine $2.5M (+32%). Commercial therapy revenue grew 53.5% to $3.9M.","Full-year 2022 revenue guidance $260-265M (17-19% growth). Cash and short-term investments $600M.","Record 609 clinical trials supported, 81 in Phase 3 (up from 69). Board authorized $100M share repurchase; 306,300 shares repurchased for $8.3M."],"consensus_eps_estimate":null,"consensus_eps_actual":-0.31,"consensus_revenue_estimate":null,"consensus_revenue_actual":52302000.0,"consensus_period":"2022-Q1","consensus_source":"xbrl_only","sentiment":"negative","materiality_score":0.75,"calibrated_materiality_score":0.75,"market_cap_usd":706640433.803725,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":365509,"accession_number":"0001104659-22-056276","cik":1124524,"company_name":"Cryoport, Inc.","ticker":"CYRX","form_type":"8-K","filed_at":"2022-05-05T23:59:59+00:00","items":["5.07"],"status":"ready","headline":"Cryoport shareholders elect directors, ratify auditor, approve executive compensation at 2022 annual meeting","summary_kind":"llm","event_type":"other","confidence":"high","bullets":["Eight director nominees elected: Baddour, Berman, Hancock, Hariri, Jagannath, Mandalam, Shelton, Zecchini; all received majority of votes cast.","Ratification of Ernst & Young as independent auditor for FY2022: 48,042,299 for, 6,749 against, 1,857 abstentions.","Advisory vote on named executive officer compensation approved: 43,353,996 for, 1,237,797 against, 13,401 abstentions.","Broker non-votes of 3,445,711 recorded on director election and say-on-pay proposals."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.1,"calibrated_materiality_score":0.1,"market_cap_usd":706640433.803725,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":385073,"accession_number":"0001104659-22-036136","cik":1124524,"company_name":"Cryoport, Inc.","ticker":"CYRX","form_type":"8-K","filed_at":"2022-03-21T23:59:59+00:00","items":["5.02","9.01"],"status":"ready","headline":"Cryoport enters employment agreement with CSO Sawicki; extends Shelton's contract to 2026","summary_kind":"llm","event_type":"leadership","confidence":"high","bullets":["Dr. Mark Sawicki enters 3-year employment agreement as Chief Scientific Officer and CEO of Cryoport Systems, LLC.","Sawicki's base salary set by Compensation Committee; no modification to existing compensation or equity.","Sawicki receives 18 months base salary and COBRA if terminated without cause or for good reason.","Jerrell Shelton's employment agreement amended: term extended to June 1, 2026; equity acceleration now covers all equity awards.","Shelton amendment also expands acceleration triggers to include termination without cause or for good reason."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.4,"calibrated_materiality_score":0.4,"market_cap_usd":706640433.803725,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":385072,"accession_number":"0001104659-22-032994","cik":1124524,"company_name":"Cryoport, Inc.","ticker":"CYRX","form_type":"8-K","filed_at":"2022-03-11T23:59:59+00:00","items":["8.01","9.01"],"status":"ready","headline":"Cryoport authorizes $100M share and convertible note repurchase program through Dec 2025","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Board authorized up to $100M repurchase of common stock and/or convertible senior notes.","Program expires December 31, 2025; repurchases at management's discretion on open market.","CEO cites confidence in business model and commitment to shareholder return.","Company does not expect to incur debt to fund the repurchase program.","Also presenting at multiple investor conferences including Roth, KeyBanc, Needham, B Riley, UBS, Jefferies."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.7,"calibrated_materiality_score":0.7,"market_cap_usd":706640433.803725,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":385071,"accession_number":"0001104659-22-026741","cik":1124524,"company_name":"Cryoport, Inc.","ticker":"CYRX","form_type":"8-K","filed_at":"2022-02-24T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Cryoport FY2021 revenue $222.6M (+183% YoY); Q4 net loss $260.1M on $251.8M debt extinguishment","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["FY2021 revenue $222.6M (+183% YoY); organic revenue from Cryoport Systems & CRYOGENE +40%.","Q4 revenue $56.4M (+17% YoY); Biopharma/Pharma revenue $46.3M (+18%).","Net loss Q4 $260.1M incl $251.8M non-cash debt extinguishment; Adj. EBITDA $0.8M.","Cash & short-term investments $628.8M at Dec 31, 2021; placed $402.5M 0.75% convertible notes.","Supports record 602 clinical trials (273 Phase 2, 74 Phase 3); fire at MVE facility expected Q1 impact $4-5M."],"consensus_eps_estimate":null,"consensus_eps_actual":-6.19,"consensus_revenue_estimate":null,"consensus_revenue_actual":222608000.0,"consensus_period":"2020-FY","consensus_source":"xbrl_only","sentiment":"positive","materiality_score":0.75,"calibrated_materiality_score":0.75,"market_cap_usd":706640433.803725,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":385070,"accession_number":"0001104659-22-017128","cik":1124524,"company_name":"Cryoport, Inc.","ticker":"CYRX","form_type":"8-K","filed_at":"2022-02-09T23:59:59+00:00","items":["8.01","9.01"],"status":"ready","headline":"Cryoport expects MVE New Prague production resumption Feb 14; $4-5M Q1 revenue impact","summary_kind":"llm","event_type":"other","confidence":"high","bullets":["Fire on Jan 25 at MVE Biological Solutions' New Prague facility halted production.","Production expected to resume week of Feb 14, 2022; full production ramp during Q1.","Revenue impact of $4-5 million limited to Q1 2022.","Insurance expected to cover majority of restoration costs and business interruption."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.65,"calibrated_materiality_score":0.65,"market_cap_usd":706640433.803725,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":385069,"accession_number":"0001104659-22-009837","cik":1124524,"company_name":"Cryoport, Inc.","ticker":"CYRX","form_type":"8-K","filed_at":"2022-02-01T23:59:59+00:00","items":["8.01","9.01"],"status":"ready","headline":"Cryoport reports fire at MVE New Prague facility; production curtailed, expects Q1/Q2 financial impact","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Fire occurred January 25, 2022 at MVE Biological Solutions' New Prague, MN manufacturing facility; no injuries reported.","Damage limited to a portion of the facility; manufacturing operations curtailed until repairs complete, date TBD.","Cryoport expects adverse financial results for Q1 and possibly Q2 2022 due to reduced operations.","Company anticipates significant share of loss covered by property and business interruption insurance.","Aluminum dewar production affected; other MVE facilities not impacted."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"negative","materiality_score":0.7,"calibrated_materiality_score":0.7,"market_cap_usd":706640433.803725,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":402950,"accession_number":"0001104659-21-138219","cik":1124524,"company_name":"Cryoport, Inc.","ticker":"CYRX","form_type":"8-K","filed_at":"2021-11-12T23:59:59+00:00","items":["1.01","2.03","3.02","9.01"],"status":"ready","headline":"Cryoport issues $402.5M 0.75% convertible notes due 2026, repurchases $100.7M 2025 notes","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Issued $402.5M principal of 0.75% Convertible Senior Notes due 2026; includes $52.5M from full exercise of initial purchasers' option.","Initial conversion rate 8.5038 shares per $1,000 principal (conversion price $117.59 per share).","Registered direct placement of 3,072,038 shares at $81.10 per share.","Agreed to repurchase ~$100.7M principal of existing 3.00% 2025 notes for ~$351.1M cash.","Notes redeemable at company's option on/after Dec 6, 2024 if stock price exceeds 130% of conversion price."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.75,"calibrated_materiality_score":0.75,"market_cap_usd":706640433.803725,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":402949,"accession_number":"0001104659-21-136567","cik":1124524,"company_name":"Cryoport, Inc.","ticker":"CYRX","form_type":"8-K","filed_at":"2021-11-10T23:59:59+00:00","items":["8.01","9.01"],"status":"ready","headline":"Cryoport prices $350M 0.75% convertible notes due 2026 and $248.6M equity placement","summary_kind":"llm","event_type":"debt","confidence":"high","bullets":["Upsized $350M aggregate principal of 0.75% convertible notes due Dec 2026; initial purchasers' option for additional $52.5M.","Initial conversion price ~$117.59 per share, a 45.0% premium over $81.10 closing price on Nov 9, 2021.","Registered direct placement of 3,072,038 shares at $81.10 with net proceeds ~$248.6M.","Net proceeds from both offerings used to repurchase ~$100.7M principal of outstanding 3.00% convertible notes due 2025.","Settlement expected Nov 12, 2021; equity placement contingent on note closing."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.75,"calibrated_materiality_score":0.75,"market_cap_usd":706640433.803725,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":402948,"accession_number":"0001104659-21-135725","cik":1124524,"company_name":"Cryoport, Inc.","ticker":"CYRX","form_type":"8-K","filed_at":"2021-11-08T23:59:59+00:00","items":["8.01","9.01"],"status":"ready","headline":"Cryoport announces $300M convertible notes offering and common stock placement; proceeds to repurchase 2025 notes","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Announces $300M convertible senior notes due 2026; initial purchasers have option for additional $45M.","Also proposes registered direct placement of common stock; completion contingent on note offering.","Net proceeds to repurchase a portion of outstanding 3.00% Convertible Senior Notes due 2025 and for general corporate purposes.","Notes will be senior unsecured obligations, maturity Dec 1, 2026, settle conversions in cash/stock at Cryoport's election.","Notes redeemable after Dec 6, 2024 if stock price exceeds 130% of conversion price and liquidity conditions met."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.65,"calibrated_materiality_score":0.65,"market_cap_usd":706640433.803725,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":402947,"accession_number":"0001104659-21-134464","cik":1124524,"company_name":"Cryoport, Inc.","ticker":"CYRX","form_type":"8-K","filed_at":"2021-11-04T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Cryoport Q3 revenue $56.7M (+407% YoY); net loss $0.18/share; 582 clinical trials supported","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Total revenue $56.7M for Q3 2021, up 407% YoY; organic growth 38%.","Net loss attributable to common stockholders $8.5M ($0.18 per share), vs $11.4M ($0.29) in Q3 2020.","Adjusted EBITDA $5.6M in Q3 2021, vs -$0.7M in Q3 2020; gross margin 41.5% vs 54.2%.","Supported 582 clinical trials (up from 561 in Q2 2021) and eight commercial therapies in regenerative medicine.","Cash and short-term investments $349.5M as of Sep 30, 2021, up from $93.3M on Dec 31, 2020."],"consensus_eps_estimate":null,"consensus_eps_actual":-0.46,"consensus_revenue_estimate":null,"consensus_revenue_actual":166168000.0,"consensus_period":"2021-Q3","consensus_source":"xbrl_only","sentiment":"positive","materiality_score":0.75,"calibrated_materiality_score":0.75,"market_cap_usd":706640433.803725,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":421865,"accession_number":"0001104659-21-100827","cik":1124524,"company_name":"Cryoport, Inc.","ticker":"CYRX","form_type":"8-K","filed_at":"2021-08-05T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Cryoport Q2 revenue $56.2M (+498% YoY); record trials, positive adjusted EBITDA","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Revenue $56.2M, up 498% YoY; organic growth 55%; Biopharma/Pharma up 431%.","Net loss $5.4M vs $5.8M loss a year ago; net loss per share $0.16 vs $0.15.","Adjusted EBITDA $5.9M vs ($2.5M) loss; gross margin 45.2% vs 54.6%.","Supporting 561 clinical trials and 8 commercial therapies; acquired F-airGate and CTSA in Q2.","Cash $349.4M after public offering; expects up to 9 MAA/BLA filings in H2 2021."],"consensus_eps_estimate":null,"consensus_eps_actual":-0.29,"consensus_revenue_estimate":null,"consensus_revenue_actual":109475000.0,"consensus_period":"2022-Q2","consensus_source":"xbrl_only","sentiment":"positive","materiality_score":0.75,"calibrated_materiality_score":0.75,"market_cap_usd":706640433.803725,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null}],"next_cursor":null}